The term thrombotic microangiopathy (TMA) defines a syndrome characterised by the association of a peripheral thrombocytopenia, a mechanical haemolytic anaemia and organ failure [1]. Thrombotic thrombocytopenic purpura (TTP) and the haemolytic uremic syndrome (HUS) (including Shigatoxin-associated HUS and atypical HUS [aHUS]) are the two most common forms of TMA. The latter can also occur in association with treatments such as antineoplastic agents, recreational drugs, or various other conditions such as transplantation, malignant hypertension or systemic auto-immune diseases (SAID).
